Related Experiment Video
Updated: Oct 8, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
11Department of Cardiology, Sestre milosrdnice University Hospital Center; 2Faculty of Dental Medicine and Health, University of Osijek; 3Faculty of Medicine, University of Rijeka; 4Faculty of Medicine, University of Osijek.
Abstract:
The leading cause of death in patients with prostate cancer are cardiovascular diseases. Androgen deprivation therapy is the mainstay of treatment in prostate cancers. The latter has numerous perplexed disadvantaging effects to cardiovascular health. ADT alternates the metabolic profile, insulin resistance and glucose metabolism, causes loss of lean body mass, an increase in adipose tissue, obesity, worsening of atherosclerosis and heart failure. It is important to point out that prostate cancer survivors have increased prevalence of coronary artery disease, cerebrovascular stroke, myocardial infarctions and cardiovascular mortality. Due to these reasons particular care on prevention and treatment of cardiovascular diseases should become a standard of care in patients with prostate cancer.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Coronary Artery Disease I: Introduction
Cardiovascular Drugs: Classification based on Therapeutic Indications
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Cardiomyopathy V: Interprofessional Care

